Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Expands bioprocessing footprint across Asia
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Captured microbes are then neutralized on engineered microbicidal surfaces
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Subscribe To Our Newsletter & Stay Updated